PROGRAM

Choosing Systemic Therapies After Chemoimmunotherapy in NSCLC

• Non-Squamous
• Squamous
• Small Cell

The Solitary Pulmonary Nodule

• Evidence Based Evaluation of the Indeterminant Pulmonary Nodule
• Biomarkers in the Evaluation of Pulmonary Nodule
• Targeting the SPN
• Bronchoscopic Treatment of SPN: Opportunities and Challenges

Pleural Effusion in a Cancer Patient

• Radiological Evaluation of Pleural Effusion in a Cancer Patient
• Role of Pleural Fluid Molecular Markers and PD-L1 Testing
• Malignant Pleural Effusion: Patient Presentation and Diagnostic Pathway
• Chemical Pleurodesis, Indwelling Pleural Catheter or Both for Malignant Pleural Effusion

Perioperative Therapy for Early Stage NSCLC

• Neoadjuvant IO Monotherapy vs. Chemo-IO
• Radiation and IO for Operable Early Stage NSCLC
• Neoadjvuant and Adjuvant Targeted Therapies
• MPR and pCR as Primary Endpoints in Neaodjuvant Trials

Value in Lung Cancer, from Screening to Treatment

• Radiation Oncology: Value and Innovation
• Lung Cancer Screening in Lower Resource Settings
• Age, Gender and Ethnicity: Disparities in Lung Cancer
• Molecular Testing, Targeted Agents and Immunotherapy in Lung Cancer: Are They Worth the Cost?

Treating Lung Cancer Where Resources Are Even More Limited (Case-Based Discussion)
Panel Discussion

Biomarkers in Immunotherapy

• Role of PD-L1 and Tumor Mutational Burden in NSCLC Immunotherapy
• Individual Genomic Alterations as Predictive Factors for NSCLC Immunotherapy
• Blood-based Biomarkers for Immunotherapy: Applications and Limitations
• Immune Contexture and Immunotherapy Response in NSCLC
• Immunotherapy Biomarkers in NSCLC: Looking into the Future

Novel Immunotherapy Strategies in NSCLC

• Novel Immunotherapy Targets in NSCLC
• Cellular Therapies in NSCLC
• Combining Epigenetic Therapy and Immunotherapy in NSCLC
• Combining Immunotherapy and Anti-Angiogenic Agents
• Combining Targeted Therapies With Immunotherapy

Immunotherapy

• We Should Choose Different Treatment Models (IO Alone, IO Combination) Based on PD-L1, TMB and Other Biomarkers
• IO/Chemotherapy or IO/IO Can Fit for All Regardless the PD-L1, TMB or Other Biomarkers
• We Should Use IO Alone as Maintenance
• We Should Use Combination of IO and Chemotherapy as Maintenance

Strategies to Increase Cure Rates in Stage III NSCLC: Optimising Checkpoint Inhibitors and Beyond

• Navigating the Evaluation of Novel Systemic Agents in Stage III Disease
• Biology Guided Adaptive Radiation Therapy (BigART) and Personalized Immunotherapy in Unresectable Stage
• Extending Durvalumab Maintenance to Special Populations

Understanding and Treating Oligometastatic Diseases

• Characterization and Classification of Oligometastatic Disease
• Timing of Systemic Therapy in OMD
• Surgery as a Component of Local Consolidative Therapy
• Radiation as a Component of Treatment for Oligometastatic Disease

The Future of Immunotherapy in Unresectable Mesothelioma

• Immunotherapy – Current State of Play (Concentrating on Current Data for First Line and Salvage Strategies)
• Molecular Profiling as Biomarker for Checkpoint Inhibitors in Mesothelioma
• Checkpoint Inhibitors – How to Combine and Which Combination is Most Promising
• BAP1 as a Biomarker - Implications for Treatment (Including Immunotherapy)

Managing Progression Free Survival

• Sexuality and Intimacy
• Preoperative Exercise Training for Patients with Non-Small Cell Lung Cancer
• Vocational Rehabilitation
• Maintaining Hope and Managing Fear of Recurrence/Progression - A Psychologist Perspective

Practice Changing Initiatives

• Managing the Psychological Needs of Patients in a Screening Service
• Delivering a Speech and Language Therapy Clinic for Lung Cancer Patients
• Enhanced Recovery after Surgery Programmes
• Developing a Care Board

Evidence Base for Symptom Management

• What Symptoms Do Patients Experience in the Lung Cancer Illness Trajectory?
• Breathlessness: Multi-Pronged Approach for a Multi-Dimensional Symptom
• Fatigue
• Cachexia
• Cough
• Anxiety and Depression: Association with Patient Outcomes and Management Approaches

Quality of Life

• Quality of Life - Does It Really Matter?
• Quality of Life Is Subjective - How Can It Be Objectively Measured?
• Quality of Life as an Endpoint in Clinical Trials in the Era of Long-Term Survival
• Strategies to Improve Quality of Life
• Early Integration of Palliative Care Is the Answer to Improving Quality of Life

Getting All NSCLCs Genotyped: How Can We Get to 100%?

• Reflex Genotyping of Advanced NSCLC: The Benefits and the Barriers
• Supplementing Tumor Genotyping with ctDNA Genotyping: What Is the Best Approach?
• Effective and Interpretable Reporting of Genotyping Results
• Engaging Lung Cancer Patients in their Molecular Testing

The New WHO Classification of Lung Tumors

• Updates in Squamous Cell Carcinoma and Neuroendocrine Tumors of the Lung
• Updates in Mesothelioma
• Updates in Lung Adenocarcinoma, Mucinous and Non-mucinous
• Updates in Molecular Pathology and Genomics of Lung Tumors

Patient-Reported Outcomes, Patient Registries and Real-World Evidence: Learning Directly from Patients

• Understanding the Feasibility of Patient Reported Outcomes
• Improving Lung Cancer Survival Through Tracking of Patient Report Outcomes
• Incorporating Patient Reported Outcomes into the Lung Cancer Registry

Joint Global Lung Cancer Coalition/IASLC Session: Hot Topics for Advocates

• A Global Picture of Lung Cancer Research
• Campaigning for Lung Cancer Screening - A Tool for Advocates
• Insights in Global Lung Cancer Patient Experience

The "How To" of Modern Tobacco Control

• The Specifics of Smoking Cessation for Cancer Patients
• Starting a Smoking Cessation Service in Cancer Clinics: Added Urgency in the Time of COVID-19
• Global Blindspots in Tobacco Control - Time for the Tobacco Free Generation Endgame

Challenges in Tobacco Control

• Heat-Not-Burn and Other Alternatives Tobacco Products - Is This the Answer?
• FDA (and EMA) Regulatory Review of Tobacco Use in Clinical Trials
• Tobacco Control in the Continuum of Cancer Care - Biologic, Clinical and Cessation Challenges

Advances in Lung Cancer Screening Through Imaging and Data Analytics

• AI-Enabled Lung Cancer Predictive Analytics - The Future of Lung Cancer Screening?
• Nodule Growth Assessment Methods as a Risk Prediction Tool
• Size Isn't Everything - Other High-Risk CT Imaging Features
• Putting It Together: Current Best Practices in the Evaluation and Follow-Up of the Indeterminate Pulmonary Nodule

Public Health Issues in Lung Cancer Screening

• Patient Perspective on Lung Cancer Screening and Health Disparities
• Defining High Risk
• How to Safely Introduce a Lung Screening Programme
• Mobile CT and Effective Screening for Underserved Populations

Surgical and Pathological Staging

• Emerging Issues in Lung Cancer Pathology (STAS, Adenocarcinoma Subclassification, Anatomic Localization of Intra-Pulmonary Non-Hilar Lymph Nodes)

CT-Surgical Field LN Comparision

• Radiographic and Surgical Staging

Beyond the TNM

• Pro-Con: Non-Anatomic Parameters Should Be Included Into Current TNM Classification (Genetic, Molecular, Histology, etc)
• Pro-Con: Non-Anatomic Parameters Should Not Be Included into Current TNM Classification (Genetic, Molecular, Histology, etc)
• Revision of N Descriptors Should Include Microscopic vs Bulky Mets, # of Mets vs Stations, Nodal Zones, etc
• Revision of N Descriptors Should NOT Include Microscopic vs Bulky Mets, # of Mets vs Stations, Nodal Zones, etc
• GGN Issues

Unmet Need Issues of Current TNM

• Methodology: Logics, Considerations…
• Multiple Pulmonary Lesions: Metastasis vs Multiple Primaries, From Martini's Criteria to Molecular Profiling
• LN Map
• Special Issues: Subsolid Tumors
• Essential TNM

Future Horizons in the Management of Small Cell Lung Cancer

• DDR/PARP as a Target
• ADCS and CAR T Therapy
• Genomics of Lung Cancer
• Novel Radiation Strategies

Targeting KRAS

• Biology of KRAS Targeting Agents
• Clinical Data for KRAS G12C Inhibitors
• Mechanisms of Resistance to KRAS G12C Inhibitors
• Emerging Mechanisms to Target KRAS Directly
• Combination Therapies to Maximize the Impact of KRAS-G12C Inhibitors”

What is the Best Treatment Strategy to Target Rare Mutations (EGFR/HER2 Insertions, METex14, METamp and NRG Fusions): TKI Versus mAb Versus ADC

• ADC
• TKI
• mAb

Heterogeneity, Metastases and Resistance

• Genomic Heterogeneity
• Phenotypic Heterogeneity
• Heterogeneity and Metastases
• Heterogeneity and Drug Resistance

Advances in Omics - Next Generation

• Small Cell Sequencing
• Proteomics
• Artificial Intelligence
• Radiomics